Proteomic and functional analysis identifies galectin-1 as a novel regulatory component of the cytotoxic granule machinery

Tiago Clemente1,2, Narciso J Vieira1,2, Juan P Cerliani3, Colin Adrain4, Alexander Luthi5, Mariana R Dominguez6, Monica Yon1,2, Tiago Clemente1,2, Narciso J Vieira1,2, Juan P Cerliani3, Colin Adrain4, Alexander Luthi5, Mariana R Dominguez6, Monica Yon1,2, Fernanda C Barrence7, Thalita B Riu8, Richard D Cummings9, Telma M Zorn7, Sebastian Amigorena10, Marcelo Dias-Baruffi8, Mauricio M Rodrigues6, Seamus J Martin5, Gabriel A Rabinovich3,11 and Gustavo P Amarante-Mendes*,1,2,5

Secretory granules released by cytotoxic T lymphocytes (CTLs) are powerful weapons against intracellular microbes and tumor cells. Despite significant progress, there is still limited information on the molecular mechanisms implicated in target-driven degranulation, effector cell survival and composition and structure of the lytic granules. Here, using a proteomic approach we identified a panel of putative cytotoxic granule proteins, including some already known granule constituents and novel proteins that contribute to regulate the CTL lytic machinery. Particularly, we identified galectin-1 (Ga1), an endogenous immune regulatory lectin, as an integral component of the secretory granule machinery and unveil the unexpected function of this lectin in regulating CTL killing activity. Mechanistic studies revealed the ability of Ga1 to control the non-secretory lytic pathway by influencing Fas–Fas ligand interactions. This study offers new insights on the composition of the cytotoxic granule machinery, highlighting the dynamic cross talk between secretory and non-secretory pathways in controlling CTL lytic function.

Cell Death and Disease (2017) 8, e3176; doi:10.1038/cddis.2017.506; published online 7 December 2017

Immune-mediated elimination of intracellular microbes and cancer cells is accomplished by a complex lytic process orchestrated by CD8+ cytotoxic T lymphocytes (CTLs) and NK cells.1–3 In response to antigen-specific recognition, biochemically defined signaling events triggered by T-cell receptor (TCR)/CD3 engagement and crosslinking of accessory molecules, leads to CD8 T-cell activation and differentiation. Subsequent TCR/CD3 stimulation results in release of a fraction of cytotoxic granules at the focal point of CTL/target cell contact, ensuring that a single CTL can kill multiple target cells in a specific fashion avoiding ‘off-target’ cytotoxic effects.1–3

Among relevant molecules that serve as effectors of CTL-mediated cytotoxicity, perforin, granzyme A and granzyme B have been shown to have major roles in killing pathogen-invaded as well cancer cells.4–7 Current knowledge assumes that perforin delivers granzymes A and B, and most certainly other granule molecules, to the cytosolic compartment of target cells.5,7,8 In particular, granzyme B has been shown to be an efficient initiator of the apoptotic machinery,9,10 whereas granzyme A may account for caspase-independent events associated with target cell death.9 However, mice deficient in any of these molecules, either alone or in combination, are still able to eradicate infected cells and some tumors,11 suggesting that alternative non-overlapping or partially overlapping pathways may have compensatory roles.

In addition to their pro-apoptotic effects, mediators released during the CTL attack may also function as immune regulators controlling the activity of other immune cells in tumor, infectious or inflammatory microenvironments. For example, β-chemokines, a CDB8+ antiviral factor and many cytokines, including interferon (IFN)-γ, and tumor necrosis factor are released by activated CTLs.12,13 In addition, regulatory mediators such as serpin PI-9 (SPI-6)14 and the lysosomal protein cathepsin B15 may contribute to protect CTLs and NK cells from their own lytic machinery. Because of the extreme complexity and incomplete understanding of the molecular mechanisms that control granule-mediated cytotoxic cell killing, identification of positive and negative regulators associated with the purified CTL/NK granule fraction may contribute to dissect the complexity of this lytic machinery with the ultimate goal of manipulating this pathway for therapeutic purposes.

Here we use a large-scale proteomic approach to identify novel cytotoxic granule proteins. Particularly, we identified...
galectin-1 (Gal1) as one of the most abundant CTL granule constituents and showed by confocal microscopy that Gal1 colocalizes with perforin, granzyme B, Lamp-1 and Lamp-2. In addition, electron microscopy images clearly indicate the presence of Gal1 at the border and inside CTL granules. Importantly, CTLs from Lgals1−/− mice display altered capacity to eliminate antigen-specific targets in vivo. Mechanistic studies suggest that Gal1 can modulate cell surface Fas ligand retention and fine tune CTL activity. This study identifies an important new component of the cytotoxic granule machinery and reveals a different level of regulation of CTL lytic function.

Results

Proteomic analysis identifies major CTL granule proteins. To identify novel mediators that control the CTL lytic machinery, cytoplasmic granules of mouse H-2d-specific cell line B6.1 were isolated as described.16 The major bands observed in Coomassie blue-stained 1D SDS-PAGE were sliced out of the gel and subjected to in-gel trypsin digestion and MS/MS analysis (Figure 1a). Because of the complexity of the samples, as each band most likely contains several different proteins, only proteins with high MS-Fit score, peptide coverage above 35% and a significant number of peptide matches were selected in this first scrutiny. Thirty-nine proteins were therefore nominated as the most abundant proteins in our CTL granule fraction (Table 1), including the expected perforin and the granzymes A, B, C, E, F and G. Although the MS/MS analysis revealed the presence of granzymes D and H in our samples (data not shown), both of the scores for these granzymes did not reach our predetermined threshold as to be considered among the most abundant proteins in our preparation. The positions of all these proteins are shown in a Coomassie blue-stained 12% SDS-PAGE gel (Figure 1b). As a single band may be composed of one or two major proteins or several minor proteins, we decided not to select bands according to their abundance or intensity as it would have been incorrect to assign relative concentration of the selected proteins based on the MS-Fit score or any data from our MS/MS analysis, including size and numbers of matched peaks.

To maximize the identification of the proteins present in our CTL granule fraction, we separated samples by 2D SDS-PAGE, using different pl gradients (Supplementary Figure 1). As most of the granzymes are highly basic proteins and comprise, as far as we know, the most abundant constituents of CTL granules, it was not surprising to find out that a large amount of proteins were not resolved by pl 3-6 and pl 5-8 IEF gradients. In fact, a strong label was always detected at the very basic rim of pl 3-6 and 5-8 gels (Supplementary Figure 1). Although we ran many pl 7-10 2D SDS-PAGE gels, none provided us with a good resolution of the basic CTL granule proteins. Therefore, it was not possible to isolate single spots of the basic proteins. However, by consistently sampling the basic edge of both pl 3-6 and 5-8 gels, we successfully identified some of the granzymes (Table 2). In addition, proteomic analysis of spots isolated from 2D gels revealed some proteins also found in 1D gel, such as cyclopophilin A, adenine phosphoribosyltransferase, translationally controlled tumor protein and heat-shock cognate 71 kDa protein (Table 2). Together, both strategies revealed a total of 246 proteins among which, we found proteins previously shown to be localized in lysosomes or cytotoxic granules as well as novel putative candidates (Supplementary Table I). Interestingly, mass spectrometry analysis revealed the presence of Gal1, a prototype β-galactoside-binding lectin, as a major protein of secretory granules (Figure 1b).

Validation of mass spec data. To validate the mass spectrometry data, we first evaluated the expression of selected proteins in the NK cell line YT and compared to the expression found in other cell lines of non-cytotoxic cell origin. Western blot analysis shows that YT cells represent the only cell line that express granzyme B (A). Remarkably, all the other proteins were more abundant in YT cells compared to the other cell lines, particularly TRAIL, galectin-3 (Gal3) and DNAse γ. The expression of the selected proteins in YT cells was confirmed by immunofluorescence (Supplementary Figure 2B). In particular, confocal as well as electron microscopy revealed that Gal1 was present inside cytotoxic granules, and colocalized with granzyme B, perforin, Lamp-1 and Lamp-2 (Figure 2).

In vivo cytotoxic assay revealed a role for endogenous Gal1 in killing specific CTL targets. The relative abundance of Gal1 in secretory granules prompted us to evaluate its role as a component of the cytotoxic cell machinery. We used an in vivo CTL assay well established in our laboratory17 based on recombinant adenosin vaccinioin to elicit specific CD8+T-lymphocyte activation and expansion. In this cytotoxic in vivo assay, target elimination is completely dependent on CD8+ T cells (Supplementary Figure 3). Importantly, elimination of CTL-specific targets was impaired in Gal1-deficient (Lgals1−/−) mice, suggesting an in vivo role for this lectin in CTL killing (Figure 3a). Similar results were obtained in vitro using CD8+ T cells isolated from wild-type (WT) or Lgals1−/− mice i.p. injected 12 days earlier with L1210 cells. Whereas CD8+ WT T cells killed around 50% of L1210 targets in vitro, Lgals1−/− CD8+ T cells eliminated around 10% of the same targets (Figure 3b). This altered lytic capacity was not due to impaired degranulation as Lgals1−/− CD8+ T lymphocytes degranulated as much as WT CD8+ T cells, as measured by CD107a externalization upon antigenic stimulation (Figures 3c and d). Moreover, reduced CTL killing observed in Lgals1−/− mice was not the result of a deficiency in specific CD8+ T-lymphocyte expansion. On the contrary, ELISPOT analysis revealed a higher frequency of IFN-γ-producing lymph node CD8+ T cells in Lgals1−/− compared to WT C57BL/6 mice, in response to cognate peptide (Figures 4a and b). In addition, the numbers of pentamer-positive CD8+ T cells were similar in WT and Lgals1−/− mice following 7 days of immunization with Ad5.β-gal (Figure 4c). Finally, CSFE staining of CD8+ T cells obtaining from WT or Lgals1−/− stimulated in vitro for 72 h with IL-2 and CD3/CD28 beads also revealed increased proliferation of Lgals1−/− cells (Figures 4d–f). Taken together, these
data suggest that although Lgals1−/− CTLs are expanded at higher frequency and are capable of degranulating properly upon specific stimulation, these cells experience limitations in killing specific targets.

CTLs lacking Gal1 show altered Fas-mediated cytotoxicity. In vivo CTL killing operates largely through perforin and granzymes via the granule exocytosis pathway, although the death receptor pathway, mainly mediated by Fas/FasL interaction also has an important role. Using WT (Fas-sufficient) and lpr (Fas-deficient) targets we confirmed this observation. Whereas more than 95% of Fas-sufficient targets were eliminated, only around 80% of FAS-deficient lpr targets were eliminated in WT immunized mice (Figure 5a). Importantly, immunized Lgals1−/− mice eliminated equally (less efficiently) Fas-sufficient and Fas-deficient targets (around 80–85%; Figure 5a). These results show that the deficiency observed in Lgals1−/− CTL killing recapitulates killing defects of Fas-deficient targets by WT mice, suggesting that in the absence of Gal1, FAS/FASL pathway seems to be inoperative.

Gal1 acts by retaining FasL on the CTL surface and preventing its internalization. To explore the mechanisms by which Gal1–glycan interactions control CTL cytotoxicity, we performed in vitro functional assays. Because FasL (CD95 ligand) is a 40 kDa type II membrane protein composed of three potential N-glycosylation sites (Asn184, Asn250 and Asn260, we hypothesized that Gal1–glycan interactions may modulate Fas–FasL interactions by specifically retaining FasL on the surface of CTLs, thereby prolonging interactions with Fas-positive target cells. Co-immunoprecipitation experiments with lysates of activated CD8+ T cells treated with recombinant Gal1 revealed specific interactions between Gal1 and FasL (Figure 5c). Notably, flow cytometric analysis of non-permeabilized cells demonstrated time-dependent retention of FasL on the surface of activated CTLs exposed to Gal1, an effect that was more pronounced at 30 min of incubation, compared to cells treated with vehicle control (Figures 5d and e), suggesting that Gal1 may contribute to prolong Fas–FasL interactions at the CTL–target interface. Thus, association of Gal1 to FasL promotes retention of this glycoprotein on the surface of CTLs.
Discussion

Exocytosis of lytic granules by cytotoxic cells is a Ca^{2+}-dependent phenomenon that occurs in a very coordinated manner, initiated by the triggering of the TCR and culminating in target-directed release of their constituents. To fully understand the molecular basis of CTL killing individual exploration of the biochemical and functional nature of purified cytotoxic granules is mandatory. Although some of the molecules are directly responsible for killing target cells, many others may be associated with positive or negative immune regulatory activities.

The data presented here comprise a comprehensive list of lytic granule components. Although our strategy is far from revealing the totality of proteins present in the granules of cytotoxic cells, it definitely disclosed key components of these highly specialized organelles. In this regard, it is important to keep in mind that MS/MS identification of complex protein mixtures is usually biased toward the most abundant proteins, as clearly shown in the case of proteomic analysis of the Arabidopsis thaliana chloroplast proteome. One of the reasons is that, although genomic approaches can use protocols designed to increase the number of copies of genes of interest, proteomic technology is still restrained by the fact that there is no available methodology to amplify proteins in any biological sample. Besides, not every protein in a given sample can be properly distinguished from others by any available methodology.

We used a combination of one- and two-dimension SDS-PAGE to maximize our chances to identify the cytotoxic granule components present on the cytoplasmic compartment of CTLs. In one hand, one-dimension analysis provided us with a picture of the most abundant proteins, based on the molecular weight of the major bands in Coomassie blue-stained gels. It is reasonable to speculate that individual bands analyzed may be composed of a number of proteins with similar molecular weight. Many of these proteins are probably concealed by the most abundant ones and, therefore, cannot be recognized in our scrutiny. On the other hand, although two-dimension analysis generates isolated spots that most likely contain a single protein, basic or acidic molecules as well as high-molecular-weight proteins are not properly resolved in 2D gels. In addition, technical difficulties limit isolation of any given organelle to (the extent of 100%) purity (homogeneity).

However, despite the intrinsic obstacles to unravel the composition of the cytotoxic granules, we have successfully identified novel granule-associated proteins as well as others.

Table 1: List of the most abundant proteins identified in 1D SDS-PAGE sample of CTL granule preparation

| Protein ID | Accession no. | MW/pl | Coverage (%) | Matched peptides |
|------------|---------------|-------|--------------|------------------|
| Heat-shock protein HSP90-beta (TSTA) | P11499 | 83 326/5.0 | 42 | 24 |
| NEDD1 protein | P33215 | 72 970/8.3 | 23 | 11 |
| BIP/GRP78 | P20029 | 72 423/5.1 | 59 | 38 |
| Heat-shock cognate 71 kDa protein | P08109 | 70 872/5.4 | 50 | 36 |
| Perforin | P10820 | 62 082/8.4 | 39 | 25 |
| T-complex protein 1/TCP-1 theta/CCT-theta | P42392 | 59 556/5.4 | 37 | 17 |
| Zinc finger protein 94 (Zip-94) | P32719 | 59 156/7.8 | 35 | 18 |
| Pyruvate kinase, M2 isozyme | P52480 | 57 888/7.2 | 50 | 31 |
| Protein disulfide isomerase A3 precursor (ERP60) | P27773 | 56 622/6.0 | 46 | 23 |
| Alpha enolase/Enolase-1 | P17182 | 47 141/6.4 | 55 | 27 |
| DNAse gamma/DHP2/LS-DNase/DNase I-like 3 | O55070 | 35 760/8.9 | 40 | 14 |
| Purine nucleoside phosphorylase/Inosine phosphorylase | P23492 | 33 277/5.8 | 54 | 18 |
| Granzyme A precursor/TSP-1/CTLA-3 | P11032 | 28 599/9.5 | 61 | 19 |
| Phosphomannomutase 2 (PMM 2) | P92237 | 27 657/6.0 | 61 | 15 |
| Granzyme F precursor/MCSP-3/CCP4 | P08883 | 27 643/9.9 | 40 | 11 |
| Granzyme E precursor/CCP3 | P08884 | 27 494/9.7 | 49 | 13 |
| Granzyme B/CTLA-1/CCP1 | P04118 | 27 470/9.8 | 50 | 15 |
| Granzyme G precursor/MCSP-1 | P13366 | 27 381/9.6 | 61 | 13 |
| Granzyme C/CCP2 | P08882 | 27 311/9.3 | 62 | 17 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) | P92099 | 24 838/5.1 | 40 | 10 |
| Ras-related protein Rab-17 | P35292 | 23 640/5.4 | 39 | 7 |
| Ras-related protein Rab-2A | P53994 | 23 548/6.1 | 57 | 9 |
| PPIase precursor/Rotamase/Cyclophilin B | P24369 | 22 713/9.5 | 56 | 15 |
| Peroxiredoxin 1 (thioredoxin peroxidase 2) | P35700 | 22 177/8.3 | 41 | 9 |
| G0S ribosomal protein L9 | P51410 | 21 882/10 | 58 | 12 |
| Ferritin light chain 1 | P23391 | 20 803/5.7 | 46 | 7 |
| Adenine phosphoribosyltransferase/APRT | P08030 | 19 763/6.3 | 58 | 9 |
| Translationally controlled tumor protein (TCTP) | P14701 | 19 462/4.8 | 42 | 12 |
| 40S ribosomal protein S10 | P09900 | 18 916/10.2 | 70 | 14 |
| Collin | P18760 | 18 560/6.2 | 69 | 12 |
| PPIase/Rotamase/Cyclophilin A | P11777 | 17 972/7.7 | 45 | 12 |
| 40S ribosomal protein S16 | P14131 | 16 356/10.2 | 68 | 11 |
| Superoxide dismutase [Cu-Zn] | P08228 | 15 943/6.0 | 54 | 9 |
| Myosin light chain alkali (MLC3nm) | Q60605 | 15 731/4.8 | 62 | 8 |
| Cystatin C | P21460 | 15 531/9.2 | 53 | 6 |
| Profilin I | P10924 | 14 957/8.5 | 46 | 8 |
| Galectin-1 | P10812 | 14 866/5.3 | 62 | 10 |
| Histone H2A | P22752 | 14 182/10.9 | 63 | 7 |
| Histone H2B | P10854 | 13 936/10.3 | 65 | 18 |
already known to be present in either CTL or NK granules. Importantly, they were all found to be associated with the organelle fraction enriched for many of the proteins known to be present in the lytic granules. Moreover, all received a high-confidence MS-Fit score and displayed significant peptide coverage.

Two major strategies have been used to assign proteins to specific subcellular compartments. The first uses confocal microscopy approaches to reveal colocalization with well-established markers. The sensitivity of this method may not allow proper labeling of proteins present at low concentration. Furthermore, if the protein is also present in any other compartment, the specific signal may be disguised. That might well be the case of a fraction of the proteins identified in this study. The second approach is based on the ectopic expression of constructs designed to contain molecular tags. Although this strategy greatly increases the detection limit for low abundance proteins, it is possible that proteins expressed in such way may not be properly folded and/or transported within the cell and, consequently, ended up in different compartment than the endogenous counterparts. Nevertheless, it is important to emphasize that the novel proteins presented in this study may not have an exclusive cytotoxic granule localization, as is clearly the case of Gal1, an immune regulatory lectin widely distributed in multiple cells, tissues and subcellular compartments.

Gal1 is a prototype member of a family of endogenous lectins, which functions intracellularly by interacting with intracellular signaling components or extracellularly by recognizing N-acetyllactosamine (Galβ1→4-GlcNAc; LacNAc) residues on a myriad of cell surface glycosylated receptors, including CD45, CD43 and CD7.23 This lectin has been implicated in the regulation of innate and adaptive immune responses through multiple mechanisms. In the periphery, Gal1 selectively dampens Th1 and Th17 responses,24,25 induces IL-10 secretion,26,27 inhibits T-cell trafficking28 and decreases antigen-presenting capacity by macrophages.24 Furthermore, exposure to Gal1 promotes the differentiation of IL-27-producing tolerogenic dendritic cells29 and favors the expansion of inducible T regulatory cells.30 Within the CD8+ T-cell compartment, Gal1 is induced in activated CD8 T cells and functions as an autocrine negative regulator of CD8+ T-cell binding, signal transduction and burst size.31 Gal1 deficiency results in increased frequency of CD8+ T cells and CD8+-mediated tumor rejection in several tumor models.32 Here we defined a novel role for Gal1 as a component of CTL lytic granules that contributes to CTL effector function. Given the complexity of CTL biology, the overall positive or negative effects of this lectin in CTL function might depend on the pathophysiologic context and the relative contribution of this lectin to different stages of CTL lifespan, including activation, expansion, granule release and contraction. In this regard, we found here that Gal1 negatively controls proliferation of CD8+ cells.

### Table 2

| Spot | Protein ID | Accession no | MW/pI | Coverage (%) | Matched peptides |
|------|------------|--------------|-------|--------------|------------------|
| 1    | β-spectrin/β-dystrom | Q62361 | 27 4425/5.7 | 27 | 65 |
| 2    | BIP/GRP78  | P20029 | 72 425/5.1 | 54 | 26 |
| 3    | Heat-shock cognate 71 kDa protein | P08109 | 70 872/5.4 | 36 | 20 |
| 4    | 75 kDa glucose regulated protein (GRP 75)/Mortalin | P38647 | 73 529/5.9 | 19 | 8 |
| 5    | Vimentin   | P20152 | 53 688/5.1 | 21 | 12 |
| 6    | Calreticulin/calregulin/ERP60 | NP_031617 | 48 136/4.33 | 53 | 24 |
| 7    | Calreticulin/calregulin/ERP60 | NP_031617 | 48 136/4.33 | 54 | 23 |
| 8    | Disulphide isomerase ER-60 | P27773 | 56 622/6.0 | 42 | 20 |
| 9    | Angiopoietin-related protein 2 precursor | Q9R045 | 57 119/7.3 | 20 | 7 |
| 10   | α-Enolase/Enolase-1 | P11032 | 28 599/9.5 | 46 | 10 |
| 11   | α-Enolase/Enolase-1 | P11032 | 28 599/9.5 | 46 | 10 |
| 12   | Cathepsin D precursor | P18242 | 44 954/6.7 | 34 | 13 |
| 13   | Cathepsin D precursor | P18242 | 44 954/6.7 | 34 | 13 |
| 14   | β-actin    | NP_001092 | 42 052/5.29 | 42 | 12 |
| 15   | Aldose reductase | P43767 | 35 733/5.7 | 24 | 7 |
| 16   | NUDIX      | NP_705789 | 25 623/9.15 | 38 | 13 |
| 17   | α-Granzyme E | P08884 | 27 494/9.7 | 26 | 5 |
| 18   | α-Granzyme A/CTLA-3/TSP-1 | P11032 | 28 599/9.5 | 41 | 9 |
| 19   | α-Granzyme A/CTLA-3/TSP-1 | P11032 | 28 599/9.5 | 57 | 17 |
| 20   | α-Granzyme A/CTLA-3/TSP-1 | P11032 | 28 599/9.5 | 46 | 10 |
| 21   | Chloride intracellular channel protein 1/NCC27/p64 CLCP | Q9Z1Q5 | 27 013/5.1 | 44 | 9 |
| 22   | Chloride intracellular channel protein 1/NCC27/p64 CLCP | Q9Z1Q5 | 27 013/5.1 | 39 | 9 |
| 23   | Proteasome subunit alpha type 1/Macropsin subunit C2 | Q9RP4 | 29 547/6.0 | 34 | 9 |
| 24   | Ubiquitin carboxy-terminal hydrolase isozyme L3 (UCH-L3) | Q9KBJ1 | 26 152/5.0 | 43 | 7 |
| 25   | Phosphoglycerate mutase 1/PGAM-B | Q9DBJ1 | 28 832/6.7 | 59 | 13 |
| 26   | α-Granzyme C/COP2 | P08882 | 27 311/9.3 | 75 | 25 |
| 27   | Triosephosphate isomerase/TIM | P17751 | 26 713/6.9 | 48 | 13 |
| 28   | Triosephosphate isomerase/TIM | P17751 | 26 713/6.9 | 40 | 9 |
| 29   | α-Transferrin controlled tumor protein (TCTP) | P14701 | 19 462/4.8 | 37 | 8 |
| 30   | α-Transferrin controlled tumor protein (TCTP) | P14701 | 19 462/4.8 | 44 | 12 |
| 31   | Adenine phosphoribosyltransferase/APRT | P08030 | 19 763/6.3 | 58 | 8 |
| 32   | α-Granzyme B/CTLA-3/TSP-1 | P08882 | 27 311/9.3 | 75 | 25 |
| 33   | Nucleoside diphosphate kinase B (NDK B)/ NM23-M2 | Q01768 | 17 363/7.0 | 68 | 9 |
| 34   | PPIase/Rotamase/Cyclophilin A | P17742 | 17 972/7.7 | 50 | 9 |

*Also identified by 1D electrophoresis.*
T cells, whereas amplifies FasL-mediated killing activity. Moreover, our findings show that Gal1 may retain FasL on the surface of CTLs, suggesting that this lectin could delay FasL endocytosis and prolong interactions with Fas-positive target cells. Interestingly, this lectin has been shown to increase cell surface residency and prevent endocytosis of various glycosylated receptors, including the CD45 phosphatase in microglia cells and vascular endothelial growth factor receptor 2 on the surface of endothelial cells. Thus, lectin–glycan interactions can amplify or interrupt cell–cell communication by modulating endocytosis, trafficking and signaling of canonical receptors. Importantly, as blockade of Gal1 in most cancer models results in CD8+ T-cell-mediated tumor rejection, it seems apparent that under conditions in which Gal1 secretion is substantially increased (i.e., tumor or inflammatory microenvironments), contraction of the CD8+ T-cell compartment and inhibition of CTL function will certainly prevail.

In conclusion, using an interdisciplinary approach ranging from proteomics search to biochemical and functional assays, we identified a novel role of Gal1 as an integral component of the CTL lytic machinery. Moreover, our proteomics strategy sets the stage for further studies to unravel the function of the newly identified proteins in cytotoxic cell degranulation, killing and immunomodulation.

Materials and Methods

Mice and ethics statement. Six- to eight-week-old WT, CD8−/− or Gal1-deficient (Lgals1−/−) C57BL/6 mice (all males) were housed at our animal facility at the Institute of Biomedical Sciences, University of Sao Paulo (ICB-USP). This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Brazilian National Council of Animal Experimentation (http://www.cobea.org.br/). The protocols were approved by the Animal Ethics Committee of the ICB-USP.

Cell culture. The L1210 and the NK line YT were maintained in RPMI-1640 supplemented with 10% FCS, 25 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin.

Antibodies and reagents. MytoTracker and LysoTracker were obtained from Molecular Probes (Eugene, OR, USA). Antibodies were from different sources. Anti-perforin (clone øG9), anti-TRAIL (clone III6F) and anti-granzyme A mAbs (clone
GA6) were purchased from Alexis Biochemicals/Enzo Life Sciences, Inc. (Farmingdale, NY, USA). Anti-Gal1 and anti-galectin-3 mAbs were obtained from R&D Systems, Inc. (Minneapolis, MN, USA). Anti-DNase \( \gamma \) mAb (Ab-1) was purchased from Oncogene Research Products (La Jolla, CA, USA) and anti-granzyme B pAb (ab4059) was from Abcam (Cambridge, UK). Anti-perforin mAb (clone CB5.4) was acquired from Apotech Co. (Epalinges, Switzerland). Anti-cofilin and anti-profilin pAbs were purchased from Cytoskeleton, Inc. (Denver, CO, USA). Secondary antibodies coupled with Alexa Red 546 or Alexa 488 were acquired from Invitrogen (Carlsbad, CA, EUA). CTL granule preparation was kindly provided by Dr. Jürg Tschopp and corresponds to formulation described in ref. 16.

Separation of granule proteins by electrophoresis. CTL granule proteins were precipitated in 13% TCA. After 1 h incubation at 4 °C, samples were centrifuged at 15 000 \( \times \) g for 15 min at 4 °C and pellets were washed twice in 1 ml of cold acetone. For 1D analysis, the dried pellets were resuspended in SDS-PAGE loading buffer (100 mM DTT, 2% SDS, 10% glycerol, 0.1% bromophenol blue and 50 mM Tris-Cl, pH 6.8) and separated by SDS-PAGE according to Laemmli.35 For 2D analysis, pellets were dissolved in IEF sample buffer (8 M urea, 4% CHAPS, 0.05% SDS, 100 mM DTT, 0.5 % Bio-Lyte ampholyte, plus a trace of bromophenol blue) and initially used to rehydrated IEF strips overnight. First dimension IEF was carried out on a Protean IEF Cell (Bio-Rad, Hercules, CA, USA) for a total of 55 000 Vh and second dimension on a Protean II xi Cell (Bio-Rad). After protein separation, gels were stained with either Coomassie brilliant blue or silver nitrate as described.36

Figure 3 Altered cytotoxic activity of Lgals1\(^{\pm/\pm}\) CD8\(^{+}\) T cells. (a) In vivo antigen-specific target elimination by WT or Lgals1\(^{\pm/\pm}\) C57BL/6 mice immunized or not with 2 \( \times \) 10\(^{8}\) PFU of Ad5/\( \beta \)-gal 8 days before. (b) In vitro killing of L1210 targets by CD8\(^{+}\) T cells obtained from the peritoneal cavity of WT or Lgals1\(^{\pm/\pm}\) C57BL/6 mice injected 12 days before with L1210 cells. (c and d) WT or Lgals1\(^{\pm/\pm}\)CD8\(^{+}\) T-cell degranulation upon antigen-specific stimulation, as measured by Lamp-1 (CD107a) externalization.

Mass spectrometry analysis. Spots were excised from silver-stained 2D gels, washed once in oxidation buffer (15 mM K\(_3\)Fe(CN)\(_6\) and 50 mM Na\(_2\)S\(_2\)O\(_3\)) and then successively in 50% methanol/40% acetic acid. After equilibration in NH\(_4\)HCO\(_3\), gel pieces were dehydrated in 100% acetonitrile and desiccated completely in Speed-Vac at low heat setting. In-gel trypsin digestion was performed overnight at 37 °C in 12 \( \mu \)l of 10 \( \mu \)g/ml trypsin in 25 mM NH\(_4\)HCO\(_3\)0.1% n-octylglucoside. Peptide mass fingerprinting was performed by MALDI-MS in a Voyager-DE PRO Biospectrometry Workstation (Applied Biosystems, Foster City, CA, USA). Tryptic fragments were spotted onto the MALDI sample probe, in the presence of \( \alpha \)-cyano-4-hydroxy-trans-cinnamic acid (Sigma, St Louis, MO, USA). Monoisotopic peptide masses were assigned and used to search the Swiss-Prot
Figure 4  Lgals1−/− CD8+ T cells displayed enhanced in vitro and in vivo proliferating capacity compared to WT cells. (a) and (b) ELISPOT analysis of IFN-γ-producing lymph node cells obtained from WT or Lgals1−/− C57Bl/6 mice immunized or not with Ad5/βgal for 7 days and in vitro stimulated with cognate peptide ICP. (c) Antigen-specific CD8+ T cells obtained from spleens of WT or Lgals1−/− C57Bl/6 mice immunized or not with Ad5/βgal for 7 days, assessed as pentamer-positive events. (d–f) In vitro proliferation of WT or Lgals1−/− CD8 T cells stimulated for 72 h with 40 U/ml IL-2 and 10 μg/ml of CD3/CD28 beads. (d) Histogram represents the peaks of CFSE dilution of dividing cell populations. Bars represent (e) average stage of division and (f) percentage of cells in different stages of divisions in response to stimulation by IL-2 and anti-CD3/anti-CD28 mAb as determined from the CFSE dilution profile in d.
were enriched using CD8α+ T cells Isolation Kit II (Miltenyi Biotec, San Diego, CA, USA) and magnetic cell separation (AutoMACS). The purity of CD8+ T cells was >85%. CD8α cells were labeled with 5 mM CFSE and stimulated in 12-well plates for 3 or 6 days with or without 40 U/ml IL-2 and 10 ng/ml LPS, and CD3/CD28 beads (Life Technologies AS, Oslo, Norway). Flow cytometry was performed in a BD FACSVerse (BD Biosciences) and analyzed using FlowJo software (Ashland, OR, USA). The average stage of cell division was calculated based on CFSE histograms gated in the CD3+ CD8+ T cells.

**Preparation of recombinant Gal1.** Purification of recombinant Gal1 was accomplished as outlined previously. Potential LPS contamination was carefully removed by Detoxi-GelTM (Pierce) and used to test with a Gal Clot Limulus Test (0.5 IU/mg, Cape Cod).

**Co-immunoprecipitation of FasL and Gal1 and flow cytometry.** CTLs were isolated from normal spleen (Mouse CD8 Cells Kit, Invitrogen cat. number 11417D) and pre-incubated with or without recombinant Gal1 (25 μg/ml) for 15 min as described. For co-immunoprecipitation, 500 μg cell lysates were incubated with 2 μg anti-FasL or isotype control antibodies (FasL sc-956; isotype control sc-2027; Santa Cruz Biotechnology, Dallas, TX, USA). The immunocomplexes were captured with Protein G PLUS-Agarose (Santa Cruz Biotechnology) and processed for immunoblotting. Cell surface expression of FasL was analyzed on a FACSAria II flow cytometry (BD Biosciences). Nonspecific binding determined with isotype-matched control antibodies is shown. Cells were cultured in V-bottom 96-well plates (Corning) in a final volume of 200 μl in duplicate, at 37 °C in a humid environment containing 5% CO2. After 8 h incubation, cells were stained for surface markers with CD3 FITC (GK1.5) and CD8 PE (clone MFL3; eBioscience, San Diego, CA, USA). Staining was performed after addition of 1 mM sodium pyruvate and 55 μM of the VNHRFTLV peptide was added. The cell viability of the cells was evaluated using 0.2% trypan blue exclusion dye to discriminate between live and dead cells. Cell concentration was adjusted to 5 × 106 cells/ml. In half of the cultures, a final concentration of 10 μM of the VNHRFTLV peptide was added. The cells were cultivated in V-bottom 96-well plates (Corning) in a final volume of 200 μl in duplicate, at 37 °C in a humid environment containing 5% CO2. After 8 h incubation, cells were stained for surface markers with CD3 FITC (GK1.5) and CD8 PerCP (53-6.7) and anti-CD107a (1D4B) antibodies on ice for 20 min. At least 105 cells were analyzed on a BD FACSCanto II flow cytometry and then analyzed with FlowJo.

**Statistical analysis.** Groups were compared using one way ANOVA followed by Tukey’s HSD test (http://faculty.vassar.edu/lowry/VassarStats.html). The differences were considered significant when the P-value was < 0.05.
Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements
We wish to thank Dr. Roger Chammas for helpful suggestions and Dr. Jürg Tschopp for providing CTL granule preparations. TC, NJV and MY were recipients of PhD fellowships from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP Brazil). This work was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq—311947/2015-6) to MDB, Investigator Award from Science Foundation Ireland to SJK, Agencia de Promocióon Científica y Tecnológica (PICT 2012, 2014) to GAR and FAPESP (2014/16352-6) to GPM.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

1. Cullen SP, Martin SJ. Mechanisms of granule-dependent killing. Cell Death Differ 2008; 15: 251–262.
2. Deackmann NM, Frazer GL, Asano Y, Stritchcombe JC, Griffiths GM. The cytotoxic T lymphocyte immune synapse at a glance. J Cell Sci 2016; 129: 2881–2886.
3. Jenkins MR, Griffiths GM. The synapse and cytolytic machinery of cytotoxic T cells. Curr Opin Immunol 2010; 22: 308–313.
4. Catalfamo M, Henkart PA. Perforin and the granule exocytosis cytotoxicity pathway. Curr Opin Immunol 2003; 15: 522–527.
5. Pardo J, Aguillo JL, Arel A, Martin P, Jeodeli L, Borner C et al. The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. Microbes Infect 2009; 11: 452–459.
6. Shresta S, Graubert TA, Thomas DA, Raptis SZ, Ley TJ. Granzyme A initiates an alternative pathway for granule-mediated apoptosis. Immunity 1999; 10: 595–605.
7. Volschenk I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 2006; 6: 940–952.
8. Khee D, Shi L, Feske S, Massol R, Navarro F, Kirchhausen T et al. Performin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity 2005; 23: 249–256.
9. Martin SJ, Amarante-Mendes GP, Green DR. Cytotoxic lymphocyte killing enters the ice age. Adv Exp Med Biol 1996; 406: 29–37.
10. Martin SJ, Amarante-Mendes GP, Shi L, Chuang TH, Casiano CA, O’Brien GA et al. The cytotoxic cell protease granzyme B initiates apoptosis in a cell-free system by proteolytic processing and activation of the ICE/ced-3 family protease, CPP32, via a novel two-step mechanism. EMBO J 1996; 15: 2407–2416.
11. Davis JE, Smyth MJ, Trapani JA. Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo antitumor capacity. J Immunol 2001; 167: 832–836.
12. Klose K, Lueken U, Kohler J, Brischwein T, Benndorf U et al. A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 2007; 13: 1131–1141.
13. Pardo J, Aguillo JL, Arel A, Martin P, Jeodeli L, Borner C et al. The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. Microbes Infect 2009; 11: 452–459.
14. Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE et al. An immunoregulatory signature in Th cells functionally defined by IL-10 expression. Immunity 2004; 20: 685–690.
15. Orlinick JR, Vaishnaw A, Elkon KB, Chao MV. Requirement of cysteine-rich repeats of the human Fas ligand in T cells and natural killer cells. J Immunol 1999; 162: 2888–2894.
16. Kieffmann T, Russenberger D, von Zychlinski A, Christopher W, Spilander K, Gruissem W et al. The Arabidopsis thaliana chloroplast proteome reveals pathway abundance and novel protein functions. Curr Biol 2004; 14: 354–362.
17. Starossc SM, Mascarenho ID, Imoto J, Cao L, Raddassi K, Hernandez SF et al. Galectin-1 deactivates classically activated macrophages and protects from inflammation-induced neurodegeneration. Immunity 2012; 37: 249–263.
18. Barrowman P, Beigier-Bompadre M, Ileriagu JM, Toscano MA, Bianco GA, Istriz MA et al. A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J Immunol 2007; 178: 436–445.
19. Blois SM, Ileriagu JM, Tometten M, Garcia M, Orsal A, Cordero-Russo R et al. A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 2007; 13: 1450–1457.
20. Cedeno-Laurient F, Oppermann M, Barthel SR, Kuchroo VK, Dimitrto CJ. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. Immunity 2004; 20: 685–690.
21. Stowell SR, Qian Y, Karmarkar S, Koyama NS, Dias-Barufi M, Leffter H et al. Differences in roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J Immunol 2008; 180: 3091–3102.
22. Norling LV, Sampaio AL, Cooper DP, Perrelli M. Inhibitory control of endothelial galectin-1 on in vivo and in vivo lymphocyte trafficking. FASEB J 2008; 22: 682–690.
23. Ileriagu JM, Crici DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009; 10: 881–891.
24. Toscano MA, Comadogaro AD, Ileriagu JM, Bianco GA, Liberman A, Sierra HM et al. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol 2006; 176: 6323–6332.
25. Liu SD, Tomassian T, Bruhn KW, Miller JF, Poirier F, Miceli MC. Galectin-1 tunes TCR binding and signal transduction to regulate CD8+ burst size. J Immunol 2009; 182: 5233–5239.
26. Baston JL, Banario RA, Ricci MA, Bilotas MA, Oliveira CN, Singla JJ et al. Targeting galectin-1 in patients with multiple sclerosis: a phase 2 study. J Pathol 2014; 234: 329–337.
27. Rubinstein I, Alvarez M, Zwinrer NW, Toscano MA, Ileriagu JM, Bravo A et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5: 241–251.
28. Soldati R, Berger E, Zenclussen AC, Joch G, Lode HN, Salatino M et al. Neutrophilastoma triggers an immunomodulatory process involving galectin-1-dependent modulation of T cell and dendritic cell compartments. J Immunol 2012; 188: 1045–1057.
29. Gal1, a component of the cytotoxic cell machinery
T Clemente et al